Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2012

01-08-2012 | Original Article

Protective Effects of 3,4-Oxo-isopropylidene-Shikimic Acid on Experimental Colitis Induced by Trinitrobenzenesulfonic Acid in Rats

Authors: Jian-Feng Xing, Jian-Ning Sun, Jin-Yao Sun, Cui-Yu You, Kai Dong, Jun Lv, Ya-Lin Dong

Published in: Digestive Diseases and Sciences | Issue 8/2012

Login to get access

Abstract

Background

3,4-Oxo-isopropylidene-shikimic acid (ISA) is a derivative of shikimic acid (SA). SA is extracted from Illicium verum Hook.fil., which has been used in traditional Chinese medicine and used for treating vomiting, stomach aches, insomnia, skin inflammation, and rheumatic pain.

Aims

To investigate the effects and the protective mechanism of 3,4-oxo-isopropylidene-shikimic acid on experimental colitis model induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in rats.

Methods

Colitis in rats was induced by colonic administration with TNBS. ISA (50, 100, and 200 mg/kg) was administered for 12 days to experimental colitis rats. The inflammatory degree was assessed by macroscopic damage score, colon weight/length ratios (mg/cm), and myeloperoxidase (MPO) activity. Malondialdehyde (MDA), glutathione (GSH), and nitric oxide (NO) levels, and superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), inducible nitric oxide synthase (iNOS) activities were measured with biochemical methods.

Results

ISA significantly ameliorated macroscopic damage, reduced colon weight/length ratios and the activity of MPO, depressed MDA and NO levels and iNOS activity, and enhanced GSH level, and GSH-Px and SOD activities in the colon tissues of experimental colitis in a dose-dependent manner. Moreover, the effect of ISA (200 mg/kg) was as effective as sulfasalazine (500 mg/kg).

Conclusions

The findings of this study demonstrate the protective effect of ISA on experimental colitis, probably due to an antioxidant action.
Literature
1.
Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol. 2007;115:1–11.PubMedCrossRef
2.
Herias MV, Koninkx JF, Vos JG, Huis in’t Veld JH, van Dijk JE. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int J Food Microbiol. 2005;103:143–155.PubMedCrossRef
3.
Monteleone G, Pallone F, Macdonald TT. Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol. 2011;11:640–645.PubMedCrossRef
4.
Araki Y, Andoh A, Fujiyama Y. The free radical scavenger edaravone suppresses experimental dextran sulfate sodium-induced colitis in rats. Int J Mol Med. 2003;12:125–129.PubMed
5.
Bitiren M, Karakilcik AZ, Zerin M, et al. Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. Biol Trace Elem Res. 2010;136:87–95.PubMedCrossRef
6.
Sener G, Aksoy H, Sehirli O, et al. Erdosteine prevents colonic inflammation through its antioxidant and free radical scavenging activities. Dig Dis Sci. 2007;52:2122–2132.PubMedCrossRef
7.
Barbosa DS, Cecchini R, El Kadri MZ, et al. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition. 2003;19:837–842.PubMedCrossRef
8.
Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–424.PubMedCrossRef
9.
Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113:427–437.PubMedCrossRef
10.
Cooke CL, Davidge ST. Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol. 2002;282:395–402.
11.
Wang HT, Jin HT, Sun JN, Guo YJ. Experimental studies on the antithrombosis effect of 3, 4-oxo-isopropylidene-shikimic acid. Acta Pharm Sinica. 2002;37:245–248.
12.
Xing JF, Sun JN, Hou JY, et al. Study on anti-inflammatory effects of 3,4-oxo-isopropylidene-shikimic acid. Chin Pharm J. 2006;41:1861–1863.
13.
Wang HT, Sun JN, Xu QP, Guo YJ. Effectof 3, 4-oxo-isopropy-lidene-shikimic acid on free radical metabolism in the brain issue of rats subjected to middle cerebral artery thrombosis. Chin Pharmacol Bull. 2002;18:569–571.
14.
Ma Y, Sun JN, Xu QP, Guo YJ. Antagonizing effect of ISA on lipid peroxidation of vein endothelial cells. J Beijing Univ Trad Chin Med. 2007;30:98–104.
15.
Wang WP, Guo X, Koo MW, et al. Protective role of heme oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol. 2001;281:586–594.
16.
Tsune I, Ikejima K, Hirose M, et al. Dietary glycine prevents chemical-induced experimental colitis in the rat. Gastroenterology. 2003;125:775–785.PubMedCrossRef
17.
Bobin-Dubigeon C, Collin X, Grimaud N, et al. Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur J Pharmacol. 2001;431:103–110.PubMedCrossRef
18.
Bozkurt A, Cakir B, Ercan F, Yegen BC. Anti-inflammatory effects of leptin and cholecystokinin on acetic acid-induced colitis in rats: role of capsaicin-sensitive vagal afferent fibers. Regul Pept. 2003;116:109–118.PubMedCrossRef
19.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.PubMedCrossRef
20.
Hagar HH, El-Medany A, El-Eter E, Arafa M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol. 2007;554:69–77.PubMedCrossRef
21.
Fridovich I. Superoxide dismutases: regularities and irregularities. Harvey Lect. 1983;79:51–75.PubMed
22.
Rotruck JT, Pope AL, Ganther HE, et al. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179:588–590.PubMedCrossRef
23.
Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal Biochem. 1982;126:131–138.PubMedCrossRef
24.
Ryoyama K, Nomura T, Nakamura S. Inhibition of macrophage nitric-oxide production by arachidonate-cascade inhibitors. Cancer Immunol Immun. 1993;37:385–391.
25.
Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004;50:81–92.PubMedCrossRef
26.
Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795–803.PubMed
27.
Chen XJ, Gu LG, Shi TP, Sun JN. Experimental study on the anti-inflammation effect of 3,4-oxo-isopropylidene-shikimic acid. Chin J Inform Trad Chin Med. 2008;15:58–60.
28.
Sun WY, Sun JN, Liu ZQ, Huang JY, Zhang WB. Effects of 3,4-oxo-isopropylidene shikimic acid (ISA) on the inflammatory reaction in rats subjected to middle cerebral artery ischemia and reperfusion and its probable mechanism. Chin Pharm J. 2005;40:678–680.
29.
Cetinkaya A, Bulbuloglu E, Kurutas EB, et al. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J Exp Med. 2005;206:131–139.PubMedCrossRef
30.
Cetinkaya A, Bulbuloglu E, Kantarceken B, et al. Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci. 2006;51:488–494.PubMedCrossRef
31.
Mei Q, Xu JM, Xiang L, et al. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J. 2005;81:667–672.PubMedCrossRef
32.
Necefli A, Tulumoglu B, Giris M, et al. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci. 2006;51:1538–1545.PubMedCrossRef
33.
Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radical Biol Med. 2002;33:311–322.CrossRef
34.
Guerin P, El Mouatassim S, Menezo Y. Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and its surroundings. Human Reprod Update. 2001;7:175–189.CrossRef
35.
Segui J, Gironella M, Sans M, et al. Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J Leukocyte Biol. 2004;76:537–544.PubMedCrossRef
36.
Kuralay F, Yildiz C, Ozutemiz O, et al. Effects of trimetazidine on acetic acid-induced colitis in female Swiss rats. J Toxicol Environ Health Part A. 2003;66:169–179.PubMedCrossRef
37.
Giris M, Erbil Y, Dogru-Abbasoglu S, et al. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. The effect of glutamine on TNBS colitis. Int J Colorectal Dis. 2007;22:591–599.PubMedCrossRef
38.
Ribbons KA, Zhang XJ, Thompson JH, et al. Potential role of nitric oxide in a model of chronic colitis in rhesus macaques. Gastroenterology. 1995;108:705–711.PubMedCrossRef
Metadata
Title
Protective Effects of 3,4-Oxo-isopropylidene-Shikimic Acid on Experimental Colitis Induced by Trinitrobenzenesulfonic Acid in Rats
Authors
Jian-Feng Xing
Jian-Ning Sun
Jin-Yao Sun
Cui-Yu You
Kai Dong
Jun Lv
Ya-Lin Dong
Publication date
01-08-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2155-y

Other articles of this Issue 8/2012

Digestive Diseases and Sciences 8/2012 Go to the issue

Original Article

Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System

Original Article

Helicobacter Pylori Infection Increases the Risk of Colorectal Adenomas: Cross-Sectional Study and Meta-Analysis

Case Report

Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

Review

Advances in the Current Treatment of Autoimmune Hepatitis

Editorial

A Much Sought-After Drug—Propofol Sedation for GI Endoscopy: Always Better but Who Cares?

Stanford Multidisciplinary Seminars

Sump Syndrome as a Complication of Choledochoduodenostomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits